Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results

Moderna (NASDAQ:MRNA) posted its earnings results on Thursday. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92, Briefing.com reports. The business had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.39) earnings per share.

Moderna Trading Down 6.5 %

MRNA traded down $3.29 during trading on Friday, hitting $46.99. The company’s stock had a trading volume of 10,256,108 shares, compared to its average volume of 4,473,774. Moderna has a twelve month low of $46.57 and a twelve month high of $170.47. The firm’s 50 day moving average price is $62.46 and its 200-day moving average price is $99.62. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The stock has a market cap of $18.06 billion, a PE ratio of -3.08 and a beta of 1.69.

Insider Activity

In other Moderna news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,184 shares of company stock valued at $238,531 over the last quarter. Company insiders own 15.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. TD Cowen decreased their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th. Barclays reduced their target price on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a report on Friday. Sanford C. Bernstein initiated coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. JPMorgan Chase & Co. dropped their target price on Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a report on Monday. Finally, Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Moderna currently has a consensus rating of “Hold” and an average target price of $93.18.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.